Overview

Troglitazone in Treating Patients With Liposarcoma

Status:
Completed
Trial end date:
2000-01-01
Target enrollment:
Participant gender:
Summary
Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Treatments:
Troglitazone